Iron isomaltoside 1000: A new intravenous iron for treating iron deficiency in chronic kidney disease

Journal of Nephrology

Volumn 24, Issue 5, 2011, Pages 589-596

  Wikström, Björn ^a   Bhandari, Sunil ^b   Barany, Peter ^c   Kalra, Philip A ^d   Ladefoged, Søren ^e   Wilske, Jan ^f   Thomsen, Lars L ^g  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HOPE HOSPITAL   (United Kingdom)

^e Mental Health Services CPH   (Denmark)

^f Varnamo Hospital   (Sweden)

^g Pharmacosmos AS   (Denmark)

Author keywords

Anemia; Chronic kidney disease; Intravenous iron treatment; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; IRON; IRON ISOMALTOSIDE 1000; MONOFER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONSTIPATION; CYST; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; FERRITIN BLOOD LEVEL; GASTROENTERITIS; HEADACHE; HEMORRHAGIC CYST; HUMAN; HYPERHIDROSIS; INFLUENZA; IRON DEFICIENCY ANEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; RENAL REPLACEMENT THERAPY; SIDE EFFECT; STAPHYLOCOCCAL BACTEREMIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VITAL SIGN;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; DISACCHARIDES; EUROPE; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958169242     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6248     Document Type: Article

References (23)

1. Hsu CY, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002;13:2783-2786.
2. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610-619.
3. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465-2473.
4. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908-1914.
5. Fusaro M, Munaretto G, Spinello M, et al. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. J Nephrol. 2005;18:72-79.
6. National Collaborating Centre for Chronic Conditions. Anemia management in chronic kidney disease: national clinical guideline for management in adults and children. London: Royal College of Physicians; 2006. Available at: http://guidance.nice.org.uk/cg39. Accessed November 24, 2010.
7. Fishbane S, Maesaka JK. Iron management in end stage renal disease. Am J Kidney Dis. 1997;29:319-333.
8. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.
9. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
10. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
11. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19(2):161-167.
12. Macdougall IC. Evolution of iv iron compounds over the last century. J Ren Care. 2009;35(Suppl 2):8-13.
13. Ganzoni AM. [Intravenous iron-dextran: therapeutic and experimental possibilities] [article in German]. Schweiz Med Wochenschr. 1970;100:301-303.
14. European Medicines Agency. ICH topic E 6 (R1) guideline for good clinical practice: note for guidance on good clinical practice. (CPMP/ICH/135/95). 2002. Available at: http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf. Accessed November 24, 2010.
15. Medical Dictionary for Regulatory Activities. Chantilly, VA, USA: Maintenance and Support Services Organization. Available at: http://www.meddramsso.com/. Accessed November 24, 2010.
16. Peebles G. Clinical management: where medicine meets management-pumping iron. Health Serv J. 2004;114:28-29.
17. Bhandari S, Naudeer S. Improving efficiency and value in health care: intravenous iron management for anemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J Eval Clin Pract. 2008;14:996-1001.
18. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-382.
19. Critchley U, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfusion Alternatives in Transfusion Medicine. 2007;9:8-36.
20. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother. 2007;41:1476-1480.
21. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis. 2006;13:199-204.
22. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis. 2008;198:336-343.
23. Parkins MD, Gregson DB, Pitout JD, Ross T, Laupland KB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection. 2010;38:25-32.